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AbstrACt
Objectives Following a diagnosis of cancer, the detailed 
assessment of prognostic stage by radiology is a crucial 
determinant of initial therapeutic strategy offered to 
patients. Pretherapeutic stage by imaging is known to 
be inconsistently documented. We tested whether the 
completeness of cancer staging radiology reports could 
be improved through a nationally introduced pilot of 
proforma-based reporting for a selection of six common 
cancers.
Design Prospective interventional study comparing the 
completeness of radiology cancer staging reports before 
and after the introduction of proforma reporting.
setting Twenty-one UK National Health Service hospitals.
Participants 1283 cancer staging radiology reports were 
submitted.
Main outcome measures Radiology staging reports 
across the six cancers types were evaluated before and 
after the implementation of proforma-based reporting. 
Report completeness was assessed using scoring 
forms listing the presence or absence of predetermined 
key staging data. Qualitative data regarding proforma 
implementation and usefulness were collected from 
questionnaires provided to radiologists and end-users.
results Electronic proforma-based reporting was 
successfully implemented in 15 of the 21 centres during 
the evaluation period. A total of 787 preproforma and 
496 postproforma staging reports were evaluated. In 
the preproforma group, only 48.7% (5586/11 470) of 
key staging items were present compared with 87.3% 
(6043/6920) in the postproforma group. Thus, the 
introduction of proforma reporting produced a 78% 
improvement in staging completeness . This increase was 
seen across all cancer types and centres. The majority of 
participants found proforma reporting improved cancer 
reporting quality for their clinical practice .
Conclusion The implementation of proforma reporting 
results in a significant improvement in the completeness 
of cancer staging reports. Proforma-based assessment 
of cancer stage enables objective comparisons of patient 
outcomes across centres. It should therefore become an 
auditable quality standard for cancer care. 
IntrODuCtIOn
Once a patient is diagnosed with cancer, the 
next steps in patient care are crucial and result 
in life changing treatment decisions such as 
intensity and radicality of therapies that can 
result in long term side effects. Such decisions 
hinge on the accuracy and completeness of 
cancer staging provided to the clinical teams 
and patient.1 2 The majority of initial cancer 
treatment plans are almost entirely based on 
radiological assessment of both the cancer 
strengths and limitations of this study
 ► This is the first study to measure the performance 
of cancer reporting by radiologists. This quality im-
provement initiative has shown that, prior to the in-
tervention of proforma reporting, crucial information 
needed to make therapeutic decisions were missing 
from 52% of radiology cancer reports. This improved 
by 78% when proforma reporting was implemented 
 ► The trial was a non-blind study and consequently 
there may have been some observer (Hawthorne) 
effect which may have also contributed to the im-
provement. If so, this effect could benefit healthcare 
in future through similar audits of the quality of can-
cer radiology reporting. 
 ► A minority of centres were unable to implement pro-
forma reporting and thus failed to improve cancer 
staging; this was due to a combination of person-
nel and information technology related barriers. 
Therefore future efforts and resources should be di-
rected towards rolling out the models of care in cen-
tres that achieved cancer reporting improvements  on
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prognostic stage and anatomic distribution of disease. 
Thus, clear documentation of imaging-derived staging 
is required of radiologists to facilitate multidisciplinary 
team (MDT)-based decisions. In most cancers, radiolog-
ical staging assessment is used to guide radiotherapy and 
surgical planning, and to select which patients require 
preoperative (neoadjuvant) chemotherapy. For example, 
in studies of patients with rectal cancer, preoperative 
radiological staging and MDT discussion increased the 
proportion of patients receiving neoadjuvant treatment, 
curative surgery rates and local disease control.3 4
Despite the importance of preoperative radiology assess-
ment, very few prospective audits of imaging reports for 
cancer have been performed but all have shown signifi-
cant deficiencies in documented staging information. A 
single-centre study found tumour resectability status in 
rectal cancer, which informs the decision for preopera-
tive chemoradiotherapy, was missing in 40/55 (73%) of 
free-text radiology reports whereas proforma reporting 
reduced this to 4%.5 An audit of practice by Ontario 
Cancer Care showed similar findings with missing data 
noted in 40% (51/128) of rectal cancer staging reports 
submitted by radiologists.6
Assessment of cancer after surgery has taken place is 
better documented. Pathologists developed the concept 
of the "minimum dataset" which set the standard for 
information that should be included in all cancer staging 
histopathology reports. Using a proforma-based systemfor 
cancer reporting by pathologists is now well estab-
lished.7–10 Previous audits of histopathology reporting of 
cancer stage have shown an increase in minimum staging 
data documented in histopathology reports from 31% to 
100% in colorectal cancer following the introduction of 
proforma reporting.11 12 Similar improvements in data 
completeness have been seen in pathology reporting 
of other cancers, such as pancreas, prostate and mela-
noma, following standardisation.13–19 The impact on 
patient outcomes was demonstrated by a study showing 
that patients with incomplete staging reports with dataset 
items missing had worse cancer survival.20 The link 
between proforma reporting and improvement in survival 
is through enabling the correct identification of high-
risk patients who can be offered further therapy. 21 As a 
consequence, minimum dataset reporting of prognostic 
histopathological data following surgery for cancer has 
become a global standard of care.11 22
Current guidelines for cancer care mandate structured 
reports for histopathology staging after surgery has been 
undertaken but there is no such standard for radiology 
cancer reporting prior to treatment by surgery or preop-
erative therapy. At present, there is neither any evidence 
of a national standard for cancer radiology reporting nor 
data on whether there is potential for improvement using 
proformas. This national quality improvement initiative 
was therefore launched through the Royal College of 
Radiologists to test whether the completeness of radio-
logical cancer assessment could be improved through a 
nationally introduced pilot of proforma-based reporting 
for a group of common cancers (CAncer Staging using 
ProformA Reporting in Radiology, (CASPAR)).
MethODs
The project was jointly initiated by the Royal College of 
Radiologists (RCR) and the National Cancer Intelligence 
Network (NCIN) and was designed in consultation with 
representatives from the Royal College of Physicians, 
Royal College of Surgeons of England and the Royal 
College of Pathologists. This collaborative proposal was 
jointly funded by the Academy of Medical Royal Colleges 
and the RCR.
This study did not require Research Ethics Committee 
approval as only anonymised patient data (MDT radiology 
reports) and National Health Service (NHS) staff inter-
view/questionnaires were used.23 The requirements of 
the Data Protection Act 1998 and the clinician’s common 
law duty of confidentiality were met by the preanonymi-
sation of all patient records by clinical care staff. Only 
centres that obtained written approval from the Trust 
Data Protection Officer (Caldicott Guardian) to release 
anonymised radiology reports to the CASPAR team for 
analysis were included. One centre did not obtain Caldi-
cott agreement and was excluded from the study.
PrIMAry ObjeCtIve
 ► To compare the minimum datasets of prognostically 
and therapeutically important staging data from radi-
ology reports before and after adoption of profor-
ma-based reporting.
seCOnDAry ObjeCtIves
 ► To determine:
 – how pilot centres implemented proforma report-
ing and any areas of difficulty;
 – the usefulness of support workshops and guidelines;
 – the clinical impact of proformas from the radiology 
MDT lead and end-users (core MDT members).
The project was conducted in the UK NHS hospitals 
by radiologists reporting newly diagnosed lung, prostate, 
endometrial, cervical, colon and rectal cancer working 
within their respective MDTs. Expressions of interest 
were sought from the UK Radiology departments via the 
RCR website and an email invitation to all RCR Regional 
Chairs, the leads of all Special Interest Groups (SIG) and 
members of the NCIN Site-Specific Clinical Reference 
Groups (SSCRG). Participating centres were selected by 
the CASPAR Steering Group to represent a spectrum of 
the UK NHS hospitals, to maximise participation from 
the 2012 strategic health authority regions, ensuring the 
ratio of non-teaching to teaching hospitals was weighted 
proportionately.
Based on the criteria above, 21 centres were selected to 
take part in the evaluation. Sample size estimate allowed 
for an expected 10%–15% drop-out rate.
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A workshop was held to launch the project, this 
provided a project overview and demonstrated the six 
pilot proformas (lung, prostate, endometrial, cervical, 
rectal and colon) (see online supplementary appendix 
1). The pilot proformas were designed by the tumour 
site leads, with input and feedback from the relevant SIG 
and SSCRG. Breakout groups were held for each tumour 
site, where the individual proformas and guidance were 
explained in greater detail. Participants were requested 
to complete feedback forms. A follow-up teleconference 
was held to answer remaining queries.
This was an interventional ‘before and after’ study. In 
order to reduce the risk of bias in reporting standards 
preproforma introduction, reports were submitted from 
3 months prior to and following the introduction of 
proforma reporting. To account for differences in the 
estimated cancer-specific diagnosis rates between centres, 
the specific periods were modified for recruiting site and 
tumour type.
Pretreatment MDT radiology cancer staging reports 
for the six cancer types were eligible for inclusion. For 
pelvic malignancies, this included local staging pelvic 
MRI reports and CT assessment for metastatic disease. 
For lung and colon cancers, this included CT report for 
both primary and metastatic disease staging. Only tumour 
staging reports as documented by the radiologist (either 
MDM radiology report, report addendum following MDM 
or staging cancer report) were acceptable. Annotations 
made by the clinical teams or MDT coordinators during 
MDT discussions were not accepted. Imaging reports 
submitted not fulfilling the above criteria were excluded.
 ► Cohort 1 (preproforma (free-text) reporting): consec-
utive patients for whom a cancer staging radiology 
report was submitted prior to implementation of 
proforma reporting.
 ► Cohort 2 (postproforma reporting): consecutive 
patients for whom a cancer staging radiology report 
was submitted following implementation of proforma 
reporting.
The radiology reports were completed by consultant 
radiologists. The study was non-blind, radiologists were 
aware of participation in the study in the preproforma 
and postproforma cohorts.
The following staff were asked to provide feedback on 
the use of the proforma reports:
 ► Radiologists who had completed at least one proforma 
report.
 ► Clinical end-users (MDT core members) who had used 
at least one proforma report for decision-making.
MDT radiology reports and staff feedback question-
naires were collected between March 2012 and April 2013. 
The project was extended from the original 3-month 
preproforma and 3-month postproforma duration to 
allow for differences in the rates of cancer incidence and 
to allow time for implementation of proformas into the 
radiology information systems (RIS).
The key minimum staging items considered essential 
to making clinical treatment decisions were defined by 
consultation with the NCIN SSCRG comprising lead 
specialist multidisciplinary representatives. Cancer-spe-
cific proforma report templates were produced to include 
these key data items considered clinically important for 
cancer treatment and prognosis (see online supplemen-
tary appendix 2). These were approved by the respective UK 
SIG and the NCIN SSCRG. The completeness of reports 
was assessed using scoring/coding forms (designed by 
project leads) that listed the presence or absence of the 
predetermined key staging data (see online supplemen-
tary appendix 3). Staging items that were not applicable 
to a particular case were deducted from the ‘total’ count 
to produce a ‘total needed’ count.
All free-text (preproforma) report scoring was carried 
out by experienced members of the project team. All 
proforma report scoring was carried out by an indepen-
dent data analyst team and queries were referred to the 
project team.
Standardised questionnaires were used to solicit staff 
feedback on the usefulness of proformas in reporting 
imaging findings (radiologists) and facilitating clinical 
decision-making (end-users).
DAtA AnAlysIs
A project database was developed by the independent 
data analyst team. The database was checked by the inde-
pendent data analyst team for completeness and checked 
against the data collection form, any missing data were 
identified and corrected as appropriate. A 10% sample of 
coded and source reports were sent to the independent 
data monitoring committee (DMC) to assess quality and 
fairness of coding of preproforma and proforma reports 
(see online supplementary appendix 4). The DMC also 
checked that recruitment was adequate to meet the 
number needed based on the three scenario power calcu-
lations (table 1).
stAtIstICAl AnAlysIs fOr the PrIMAry enD POInt
Hypothesis: the introduction of proforma reporting 
improved the completeness of reporting in the cancers 
tested by an expected 20% with an expected completeness 
rate preproforma of 50% (based on a previous internal 
audit). A difference in the percentage of completed data 
items between proforma and non-proforma reports of at 
least 20% following proforma introduction required a 
sample size of 124 cancer reports per cancer type prior 
Table 1 Power calculations
Proportion 
difference Power (%) Significance (%)
Sample size 
needed
0.10 90 5 518
0.20 90 5 124
0.30 90 5 51
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to and after the introduction of proforma reporting, with 
90% power and 5% significance.
Sample size calculations with variable proportion 
differences in completeness of reports to achieve at 
least 90% power and 5% significance were calculated as 
mentioned in table 1.
Thus, a total of 248 (124 free-text and 124 proforma) 
cancer reports per cancer type were required to show an 
increase of 20% completeness of reports between prein-
tervention and postintervention cohorts.24
Primary objective
Differences in completeness of reporting of the 
predefined minimum staging data were calculated 
before and after proforma implementation. The data 
were analysed for the whole sample and stratified by 
tumour site and reporting hospital. The 95% CIs for 
proportions of completed data items were calculated by 
the method of Wilson.25 Differences in proportions of 
completed data items preproforma and postproforma 
reporting were calculated and CIs for these differences 
calculated using method 10 of Newcombe.26
secondary objective
A qualitative analysis through questionnaire responses 
was undertaken to evaluate the secondary objectives.
results
The study flow and landmarks are summarised in figure 1. 
A total of 36 radiology departments expressed an interest 
in taking part in the evaluation. Twenty-one centres 
attended the launch meeting workshop and enrolled to 
participate in the project.
Primary end point
Two centres (5 and 16) failed to supply any data, 62 
preproforma and 3 proforma reports did not comply with 
the inclusion criteria, and were excluded.
Nineteen centres provided preproforma free-text 
reports for inclusion in the study (table 2). Of these, 
four centres provided preproforma reports only (centres 
6, 8, 14 and 21). In total, 15 of the 19 centres provided 
both preproforma and postproforma reports for at least 
two tumour types (table 2). The total number of reports 
provided by cancer type is summarised in table 3.
The total number of preproforma reports for cervical 
and endometrial cancer and postproforma reports for all 
of the tumour types was less than 124.However, following 
review of the data by the DMC, the CASPAR group were 
advised to stop collecting data as the sample size had 
met the endpoint of showing a significant improvement 
in staging items for all cancer types including cervical 
cancers. 
A total of 787 preproforma and 496 postproforma 
staging reports met inclusion criteria for analysis. The 
proportion of completed staging data from 787 prepro-
forma staging cancer reports were 5586 of 11 470 staging 
items (48.7%), compared with 6043 of 6943 staging items 
using proforma reports (87.3%). The improvement in 
cancer staging achieved by proforma reporting amounted 
to an absolute increase of 38.6% (95% CI 37% to 40%). 
Thus, the overall improvement was significant and 
surpassed 30%. A significant improvement in complete-
ness of reporting was not only observed for each cancer 
type but was also seen in each one of the 15 centres that 
submitted both pre- and post-proforma reports (table 
1 andtable 2).
An improvement in completeness was seen across all 
tumour types, and the improvement was >30% for four of 
the six tumour types (table 3). For lung cancer however, 
the percentage improvement was lower but still signifi-
cant at 14% (95% CI 12% to 17%), this probably relates 
to the high percentage completeness of the preproforma 
lung cancer staging reports (76.6%). For cervical cancer, 
the improvement in completeness was still significant at 
34%; for the 46 patients assessed.
The distribution of elements of staging data by cancer 
site is summarised in online supplementary appendix 
5, tables 1-6). For lung cancer, two staging items (differ-
entiation from consolidation and metastases) were less 
complete on the proforma reports compared with free-
text reports, but the difference was small: 3% and 7%, 
respectively. There were no other instances of a decrease 
in the completeness of staging items when proforma 
reports were compared with preproforma reporting.
For lung cancer staging, significant improvements in 
2/17 minimum data cancer staging items were observed. 
There was a notable improvement in the documentation 
of endobronchial and pleural disease using proformas. 
Prostate proforma introduction saw 30% or greater 
improvement in 9/13 staging items, of particular clin-
ical relevance was the improvement in documentation 
of local invasion and tumour, node, metastases (TNM) 
stage. Proforma reporting of endometrial cancer 
produced a 30% or greater improvement in reporting 
of 12/18 staging items. The most striking improvements 
were in involvement of the serosa and pelvic organs, all 
crucial to surgical decision-making and prognosis. For 
cervical cancer, an improvement of >30% was seen in 
9/17 staging items following proforma reporting. One of 
the greatest improvements was for pelvic side wall inva-
sion, a predictor of pelvic nodal involvement. For rectal 
cancer staging proforma reports, improvements were 
seen in 13/15 staging items including extramural spread 
and extramural vascular invasion. Both are important 
prognostic markers and guide selection for neoadjuvant 
therapy. Marked improvement in 10/13 staging items was 
seen by the use of the colon cancer proforma reports. 
The greatest improvements were for peritoneal infiltra-
tion and resectability—both critical for surgical  success.
A wide range of percentage completeness in individual 
reports was seen, before and, to a lesser degree, after the 
introduction of proformas. For example, the range of 
completeness of lung cancer report was 25%–100% (prepro-
forma) and 56%–100% (postproforma) and for prostate 
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was 0%–92% (preproforma) and 33%–100% (postpro-
forma). This probably, at least in part, reflects the differ-
ence in reporting style between individual radiologists. 
The effect of proforma reporting was not studied in indi-
vidual radiologists. The range of percentage complete-
ness reduced and the mean completeness increased for 
all cancer types after the introduction of the proforma. 
However, it is noted that even in the postproforma cohort, 
there were incomplete reports. It is unclear, without further 
assessment, the reasons for this. Possibilities include diffi-
culties in using the proforma, inexperience or uncertainty 
in evaluating certain parameters or it could reflect limita-
tion of the imaging modality.
secondary end points
Some queries raised regarding the lung staging proforma 
were resolved by teleconference. For the remaining 
cancer-specific workshops, 100% of the attendees agreed 
Figure 1 Study flow and landmarks. RCR, Royal College of Radiologists.
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that ‘the presentation given in this session was very clear’ 
and 80%–100% agreed that ‘they can see how (they) 
can use this proforma in clinical practice’. There was 
an average of 67% agreement among the workshop 
attendees that ‘(they) feel confident to explain the use of 
this proforma to colleagues’.
During the study, six sites reported problems encoun-
tered with implementation of the proforma into their 
RIS systems. These included unavailability of the software 
upgrade within the project timeframe. For one site, the 
RIS system did not use voice recognition so paper versions 
of the template were manually completed.
Feedback was received from 11 of 21 centres partici-
pating in the launch meeting. All sites indicated moderate 
to strong agreement that the proformas were self-explan-
atory, included all key items and improved report quality. 
Feedback from those centres unable to submit proforma 
reports is summarised in box 1. Suggestions for improving 
proforma design included: mechanisms to document 
equivocal findings, reduce the time taken document 
negative findings and to include incidental findings. For 
three sites, inability to engage colleagues and time pres-
sure were cited as limiting factors and four sites indicated 
that lack of IT support from RIS suppliers resulted in 
failure to implement the proformas. Technical barriers 
to integration of proforma report templates into existing 
RIS is clearly an important obstacle to implementation.
End-user feedback was received from 35 MDT partic-
ipants (across seven centres), including surgeons, 
medical and clinical oncologists and CNS (figure 2). 
Most respondents, 27/35 (77%), found proforma 
reports contributed positively to cancer staging, 27/35 
(77%) and 28/35 (80%) agreed they improved MDT 
efficiency and data collection, respectively. Interestingly, 
15/35 (43%) end-users felt that proforma reports had 
no impact on diagnosis, this maybe because diagnosis 
is often multifaceted, that is, also based on clinical 
examination and histological information. Feedback 
was received from 32 MDT lead radiologists (figure 3), 
26/32 (81%) respondents found it a worthwhile exer-
cise and 16/32 (50%) felt proforma reporting improved 
the quality of their reports, whereas 5/32 (16%) 
respondents did not feel it improved quality and 9/32 
(34%) were neutral. Eighteen of 32 (56%) radiologists 
reported no technical difficulties completing the form. 
However, of 28 responses, the majority, 20/28 (71%) 
found proforma report took longer to complete than 
free-text reports (figure 4).
Table 2 Percentage of data fields completed by centre
Centre
Pre Post
Proportion 
difference in 
completeness 95% CI
Total 
number 
of 
reports
Number of 
data items 
completed
Total 
needed
Total % 
completeness
Total 
number 
of 
reports
Number of 
data items 
completed
Total 
needed
Total % 
completeness
1 62 401 920 43.6 34 312 440 70.9 0.27 0.22 to 0.32
2 18 109 265 41.1 30 390 433 90.1 0.49 0.45 to 0.55
3 40 225 523 43.0 18 226 240 94.2 0.51 0.45 to 0.56
4 52 373 717 52.0 52 672 718 93.6 0.42 0.37 to 0.46
5 0 - - - 0 - - - NA NA
6 12 127 201 63.2 0 - - - NA NA
7 84 516 1210 42.6 45 559 702 79.6 0.37 0.33 to 0.41
8 56 447 899 49.7 0 - - - NA NA
9 32 268 508 52.8 56 884 917 96.4 0.44 0.39 to 0.48
10 20 126 295 42.7 23 274 352 77.8 0.35 0.28 to 0.42
11 57 495 836 59.2 45 507 586 86.5 0.27 0.23 to 0.32
12 41 317 602 52.7 27 391 419 93.3 0.41 0.36 to 0.45
13 43 347 600 57.8 36 432 460 93.9 0.36 0.31 to 0.40
14 45 252 648 38.9 0 - - - NA NA
15 61 452 879 51.4 44 440 550 80.0 0.29 0.24 to 0.33
16 0 - - - 0 - - - NA NA
17 72 500 1053 47.5 20 238 272 87.5 0.40 0.35 to 0.45
18 36 224 519 43.2 27 279 302 92.4 0.49 0.44 to 0.54
19 14 69 186 37.1 16 203 210 96.7 0.60 0.52 to 0.66
20 20 106 281 37.7 23 236 319 74.0 0.36 0.29 to 0.43
21 22 232 328 70.7 0 - - - NA NA
Total 787 5586 11 470 48.7 496 6043 6920 87.3 0.39 0.37 to 0.40
NA, not available. 
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box 1 summary of suggestions for improvement from 
participating sites
Proforma design
 ► Include a section for documenting other findings (site 3).
 ► An alternative approach might be to follow an algorithm only spe-
cifically mentioning positive findings as they are observed, rather 
than producing a report characterised by a long list of negative find-
ings (site 17).
 ► Very comprehensive many more items included than normally ex-
plicitly mentioned in my usual reports.
 ► Comprehensive but much more time consuming than our current 
(site 17, 21).
support guidance
 ► More detailed guidance would have been helpful(site 4).
Ability to report equivocal findings
 ► Ability to state equivocal findings. Proforma does not work well in 
cases which are not definite cancers or where there is uncertainty 
(site 4, 17, 21).
Importance of proforma reporting
 ► Although unable to implement the proforma, this is considered im-
portant to standardise the reporting of cancer without missing many 
important or relevant findings. In some respects, they are a good 
template for primary reporting, not just for reviews. Proforma report-
ing in principle is a good idea (site 4, 17).
 ► The reporting format should be made available to RIS/PACS 
all over National Health Service and should be mandatory 
(site 4).
Constraints in implementing proforma due to work 
pressures
 ► Heavy workload. Have lost colleagues. Concerns over prescriptive 
proforma-based reporting (site 3).
 ► Cannot force colleague radiologists to do it (site 4).
 ► One to one conversations and email reminders to colleagues. Most 
colleagues made one attempt to complete a proforma report and 
abandoned it due to the amount of time required compared with 
unstructured reporting. Not prepared to reconsider despite attempts 
to persuade them (site 17).
Commercial rIs implementation problems
 ► RIS not supportive of proforma. We explored possibility of setting up 
a template, but given the potential difficulties, we went for a prag-
matic solution of manually filling in proformas alongside radiology 
report (site 3).
 ► The forms had to be scanned on CRIS—not ideal. In support of the 
concept but the only way it can work is if it is tightly integrated into 
CRIS so the radiologist can electronically tick the boxes as images 
are reported. HSS have still not incorporated the proformas into CRIS 
for digital reporting; if they had, I feel we could all be persuaded to 
continue to use the proformas whenever possible/routinely. Early 
implementation in a PACS/CRIS friendly format is what I look for-
ward to. Enthusiasm was very high in our department but the lack of 
integration into CRIS has meant that participation will not be ongo-
ing until we can integrate (site 4).
 ► Sunquest RIS did not have ability for e-form, but we did put equiv-
alent of proformas on VRS for endometrium, cervical and pros-
tate. The RIS system was complicated and the reports produced 
were not user-friendly. The report produced in our RIS system looked 
very cluttered and found them very difficult to follow (site 21).
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DIsCussIOn
Main findings
The study has shown that proforma-based reporting was 
successfully implemented in 15 of the 21 centres with 
1283 cancer staging reports submitted. The implementa-
tion resulted in a significant global improvement in the 
proportion of prognostic and therapeutically important 
cancer imaging features reported by radiologists—from 
48.7% completeness using free-text reports to 87.3% 
using proformas, showing a 78% improvement in staging 
completeness. Improvements were seen across all the 
cancer types and all 15 centres. Since the quality of this 
information drives preoperative cancer treatment deci-
sions, this has profound implications for the quality of 
care in patients with newly diagnosed cancer. Proforma 
reports also improved the consistency of completeness of 
cancer staging data.
Of the preproforma report cohort, lung cancer had 
the greatest completeness (75%). This was the only 
cancer type that did not have a >30% improvement 
following proforma reporting (a 14% improvement 
was still observed) . A possible explanation for this is 
that lung cancer is the the most common cancer in the 
UK; furthermore, the TNM staging system is very clear 
Figure 2 MDT end-user rating of impact of proforma reporting (n=35). MDT, multidisciplinary team.
Figure 3 Multidisciplinary team lead radiologist’s rating of proforma reporting (n=32).
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and comprehensive and is the only classification that is 
included in the core curriculum for radiology trainees.27 
Thus, most radiologists, whether they attend the MDT or 
not, will be familiar with staging lung cancer and have a 
practised approach to reporting.
Study feedback reflected high acceptability of struc-
tured reports. The clinical teams that make treatment 
decisions based on radiological assessment of cancer 
found proforma reports helpful for treatment planning 
and MDM efficiency. A few centres reported inability 
to deploy the template proformas into RIS systems as a 
major barrier. The majority of radiologists considered 
proforma reporting more time consuming than free-
text reporting. Highlighting once again that one of the 
perceived major obstacles to uptake by radiologists is 
increased time needed to complete a proforma report. 
Arguably, free-text reporting is faster when there is so 
much missing information and would take much less 
time to produce compared to more detailed structured 
reports. If it is accepted that a radiology cancer staging 
report should include all the prognostic information 
to manage a patient with cancer, then it is logical to 
conclude that a prepopulated template with the required 
information set out will be much faster to complete than 
a free-text report. On the other hand, it seems likely that 
a structured template would be time saving for those 
radiologists already undertaking comprehensive free-text 
reporting. To produce radiology cancer staging reports 
of a better quality and standard may take more radiology 
time, but given the importance of cancer imaging assess-
ment in treatment decision making providing such levels 
of detail routinely would inevitably improve patient care. 
Our audit has revealed that if preproforma reports had 
been used in MDMs they would not have met the national 
standards for MDM working. Thus, when staging items 
are missing on cancer staging reports, the radiologist 
taking the MDT must provide this information. The extra 
time taken to do this, which will be proportional to the 
amount of missing data, is rarely acknowledged.
Proforma reports also provide an educational resource, 
especially for radiologists and trainees who do not 
regularly attend the relevant cancer MDM and so may 
not appreciate the staging items pertinent to clinical 
decision-making.
Progress in cancer treatment has been paralleled by 
developments in imaging technology that enable more 
accurate and detailed radiological evaluation. Despite the 
increase in the complexity and amount of information 
that needs to be interpreted and conveyed by the radiolo-
gist, the reporting style has largely remained unchanged 
from its original free prose format. While the deficiencies 
in some reports may be rectified on MDM review, this is 
not a reliable or efficient method and is inconsistently 
documented. Currently, only clinical T, N and M data are 
recorded for the cancer registries. Consequently, it may 
not always be possible to determine the basis on which 
treatment decisions for patients were made.
strengths and weaknesses in relation to other studies
Previous studies have highlighted deficiencies in cancer 
staging information from free-text reporting for various 
cancer types.28 29 Furthermore, studies have shown struc-
tured reports to improve completeness and clarity.13–19 30–32 
A study of radiological assessment of pancreatic cancer 
showed proforma reporting improved assessment of 
resectability and confidence in treatment decisions.29
The management options in cancer treatment are ever 
increasing, and there is now an established evidence 
base for the selective use of preoperative treatment to 
improve outcomes in many cancers.21 However, there 
remain wide variations in cancer care and outcomes in 
the UK, as demonstrated for lung cancer management in 
a recent large UK study.33 Radiology proforma reporting 
could improve cancer staging data available for national 
Figure 4 Radiologists’ feedback on time taken to complete proforma reports (stratified by number of reports completed 
(n=28)).
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cancer statistics, which in turn could be used to identify 
the causes of variation in cancer care.
The pathology model has shown that a structured report 
template provides an effective conduit for capturing 
and storing data, which in turn is easier to extract and 
view.14 34 Structured radiology cancer reporting provides 
high-quality and more complete information that is 
more conducive to data gathering. With the increasing 
emphasis on healthcare systems to demonstrate regular 
and robust quality assessment followed by improvement, 
the structured format is well suited to audit and research. 
It also facilitates the development of ‘bioregistries’ and 
tumour databanks.
strengths and weaknesses of this study
Four of the 19 participating sites failed to show an 
improvement in cancer reporting by proforma imple-
mentation. Feedback indicates that these four sites strug-
gled to overcome barriers to proforma implementation 
– such as technical difficulties with integration into RIS 
and poor uptake/time pressures by reporting radiolo-
gists. However, with similar constraints, 78% of hospitals 
not only managed to implement the proforma reporting 
but also demonstrated an overall 80% improvement in 
the completeness of cancer reports.  Therefore, it should 
be possible to roll-out and overcome technical and 
personnel difficulties by modeling the successes achieved 
in pilot sites. The difficulties with integration of proforma 
templates into IT systems will need to be addressed by 
commercial RIS providers. They will need to ensure 
there is an effective user-template interface so that using 
templates in regular reporting practice is easy and effi-
cient. Despite using proformas, some staging information 
was still incomplete, even in users that volunteered to 
participate in the study. We hope that in future this would 
be corrected by improvements in radiology user interface 
software which will not permit a report to be signed off 
unless all fields have an entry. 
Undoubtedly, the advances in software through artifi-
cial intelligence and machine learning will enhance the 
prospects of delivering comprehensive cancer staging 
by radiologists at diagnosis and in time for initial critical 
therapeutic decision.
 A further limitation of our study is that while improving 
the content and quality of the report through measuring 
completeness, it was beyond the scope of this study to 
assess the accuracy of individual reports and indeed the 
greater task of whether this translates into improved 
outcomes. However, the the accuracy and limitations 
of these modalities in cancer staging have already been 
extensively evaluated and staging items included in 
proforma reports have already been previously validated 
in terms of  prognostic accuracy .2 Therefore, we could 
infer that by their routine inclusion in staging reports, 
it is likely that treatment stratification, and thus patient 
outcome, would be improved. 
The implementation of the structured reporting 
template was a non-blinded intervention, thus the degree 
of report completeness, including in the preproforma 
cohort, may have been inflated by the process of this as 
an audited measure (a Hawthorne effect). Arguably, an 
ongoing “Hawthorne effect” could also be an advantage of 
introducing standardised proforma reporting as a nation-
ally audited quality measure of excellence in cancer care. 
Implications for doctors and policy makers
The Royal College of Radiologists CASPAR working group 
have shown that minimum dataset cancer staging radiology 
reports, like pathology minimum dataset reports, should 
be a mandatory standard for patients with newly diagnosed 
cancers. This model of proforma reporting is amenable 
to modifications, and could be expanded to other cancer 
types, developed with the input of relevant cancer special-
ists. In the future, the aim should be towards developing 
evidence-based validated reporting templates with a stan-
dardised structure and content including expert consensus 
agreed essential reporting elements.
Structured proforma reporting clearly improves the infor-
mation available that is needed for patient care. To facili-
tate proforma template implementation and utilisation on 
a national scale, support through education, training and 
IT infrastructure improvements will be needed. This will 
require collaboration between RIS providers and the RCR. 
Manufacturers need to improve functionality to enable 
easier integration of proforma report templates into RIS/
IT systems to ensure that proforma reporting can be imple-
mented efficiently without becoming burdensome or time 
consuming for radiologists.
Sufficient resource will be necessary to test and main-
tain radiologists’ competence in such a crucial component 
of cancer care to safeguard the consistency of standards. 
Measuring the quality and accuracy of radiology reports 
against pathology (where available) and outcomes will 
contribute to this.
unanswered questions for future research
Clinical research has already established that items 
recorded on proforma are of prognostic significance. A 
consistent system of recording cancer features as seen 
on imaging and collating this nationally will be an effec-
tive means of driving improvements in cancer care. The 
accuracy, consistency and completeness of radiological 
assessments by individual radiologists could be measured 
against patient outcomes and detailed analysis of data 
retrieved from radiology proformas may help us to better 
understand the wide variations currently observed in 
cancer patient outcomes 
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